Videos

Matthew D. Galsky, MD, discusses targeted therapy treatments for bladder cancer.

Kristi McIntyre, MD, a physician with Texas Oncology, discusses the results of a phase II, multicenter, single-arm study looking at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, discusses the utility of PET imaging for the treatment of patients with prostate cancer.

Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

Matthew J. Ellis, MD, PhD, discusses the ongoing phase III FALCON trial.

Alice T. Shaw, MD, PhD, from Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors such as LDK378 and the treatment of ALK-positive lung cancer patients with crizotinib.

Nicholas Turner, PhD, consultant medical oncologist, The Royal Marsden Hospital, London, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.

Marcia S. Brose, MD, PhD, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses clinical trial endpoints and individualizing treatment in patients with ovarian cancer.

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the role of radiation for the treatment of pancreatic cancer.

Mark J. Levis, MD, PhD, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia.

Marcia S. Brose, MD, PhD, Abramson Cancer Center, University of Pennsylvania, discusses BRAF mutations in thyroid cancer.a

Richard S. Finn, MD, discusses current research in triple-negative breast cancer

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy for renal cell carcinoma (RCC).

Naiyer A. Rizvi, MD, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses new approaches to the management of metastatic bladder cancer.

Evan Y. Yu, MD, discusses the role of PET imaging in prostate cancer.

Frederick Alan Rapoport, MD, discusses the results of the SALT 1 and SALT 2 studies, which measured the efficacy of tolvaptan (Samsca) in patients with euvolemic and hypervolemic hyponatremia

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.

Matthew D. Galsky, MD, discusses the potential role of ipilimumab for the treatment of advanced bladder cancer.

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the identification and treatment of ovarian cancer.

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, comments on the treatment of patients with hairy cell leukemia.

Alice T. Shaw, MD, PhD, discusses using crizotinib to treat patients with ALK-positive lung cancer.

Lawrence N. Shulman, MD,discusses the results of the CALGB 40101 trial.

Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting KRAS in colorectal cancer.

Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses novel agents that are currently under investigation for the treatment of gastrointestinal stromal tumors

Antoni Ribas, MD, PhD, discusses the development process of PD-1 antibody MK-3475 in melanoma.

William Kevin Kelly, DO, discusses the role of chemotherapy in castration-resistant prostate cancer.